Latest China News

AdAlta has engaged specialist advisors to streamline US FDA regulatory processes for its CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients.

Evion Group confirms high-grade fluorspar assays up to 88.15% CaF2 at its Carp Project in Nevada, validating a large, near-surface mineralised system. The company plans an extensive exploration program to capitalise on the US critical minerals demand.

Radius Residential Care has syndicated its bank debt, boosting facility limits by NZD 30 million and cutting financing costs by 65 basis points to support its growth plans, including a new care home acquisition and development projects.

TruScreen Group has secured NZ$1.82 million through an oversubscribed placement, underscoring investor confidence amid its global cervical screening expansion. The company also announced a renounceable rights issue and attaching options, both subject to shareholder approval.

Vmoto Limited disclosed it held only one formal board meeting in FY25, relying heavily on circular resolutions, and outlined plans to increase meeting frequency in 2026. The company clarified its trade insurance arrangements and affirmed director independence amid ASX queries.

Godolphin Resources is spinning out its Narraburra Rare Earths Project into a new ASX-listed entity, Matrix Critical Minerals, with MST Financial appointed to spearhead the IPO expected in the second half of 2026.

Appen Limited's FY25 results reveal solid revenue growth driven by generative AI projects and a standout performance from its China segment. The company sets FY26 revenue guidance of $270-300 million, underpinned by operational efficiencies and expanding AI data services.

Right Resources has identified a significant high-grade tungsten system at its Blue Prospect in NSW, with rock chip assays reaching 4.3% WO3 and a large soil anomaly still open in all directions.

Australian Dairy Nutritionals has locked in a $1.5 million secured loan facility with RELI Capital to shore up working capital and support its FY26 strategy, using its Yaringa dairy farm as collateral.

Australian Agricultural Company (ASX:AAC) defies North Queensland floods to deliver a 23% jump in operating profit, driven by strong beef pricing and herd valuation gains.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

TruScreen Group Limited has kicked off a NZ$2.9 million capital raising combining a NZ$1 million placement and a NZ$1.94 million rights issue to fund its global expansion and regulatory compliance efforts. The company reported a 42% jump in product sales for FY2026 and is targeting major public health programs across 14 countries.